期刊
JOURNAL OF DERMATOLOGICAL TREATMENT
卷 29, 期 3, 页码 310-313出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/09546634.2017.1360991
关键词
Carvedilol; rosacea; flushing; erythema; long-term treatment
类别
资金
- AbbVie
- Bayer Healthcare
- Galderma
- La Roche-Posay
Background: The treatment of persistent erythema and flushing episodes in patients with rosacea remains a clinical challenge. A possible therapeutic option could be the use of antihypertensive drugs. Objectives: We therefore evaluated the effect of the non-selective beta-blocker carvedilol in five Caucasian patients. Methods: In a monocentric retrospective case study, the patients were treated with carvedilol titrated up to 12.5mg twice a day over at least six months. Patients self assessment (PSA), clinicians erythema assessment (CEA), and the patients levels of embarrassment and satisfaction were performed by questionaires. Results: The CEA grade description as well as the PSA grade description decreased remarkably in all five patients. Furthermore, all patients reported to have a major improvement of their level of satisfaction and no feelings of embarrassment anymore. Conclusions: These findings demonstrate that facial flushing and persistent erythema can be effectively treated by carvedilol long-term with a fast onset of improvement in a dose well tolerated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据